Verastem Gets FDA Fast-Track Approval on Lung Cancer Treatment
By Dean Seal
Verastem Oncology said federal regulators have granted their fast-track designation to a combination of the company's avutometinib with Amgen's sotorasib for the treatment of non-small cell lung cancer.
The Boston-based biopharmaceutical company said the special status from the Food and Drug Administration will fast-track the development of the combination for patients with KRAS G12C-mutant metastatic non-small cell lung cancer who have received at least one prior systemic therapy and haven't previously been treated with a KRAS G12C inhibitor.
The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
"Given that KRAS G12C is the most common KRAS mutation in NSCLC, the advancement of the combination is important in understanding potential new treatment approaches," Chief Executive Dan Paterson said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 18, 2024 16:31 ET (21:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing